The outcome of macroprolactinomas resistant to dopamine agonists

The outcome of macroprolactinomas resistant to dopamine agonists

Aim: The present study aims to assess the final outcome after combined therapeutic approaches in patients with macroprolactinoinas resistant to dopamine agonists (DA). Patients: Records of patients with macroprolactinoma hospitalized in the Institute of Endocrinology, Bucharest, between 1978-2005, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coculescu, M, Anghel, R, Trifanescu, R, Voicu, D, Karavitaki, N, Wass, J
Formato:	Journal article
Lenguaje:	English
Publicado:	2005

Ejemplares similares

Macroprolactinoma resistente aos agonistas dopaminérgicos: relato de caso Macroprolactinoma resistant to dopamine agonists: a case report
por: Rosana Maria dos Reis, et al.
Publicado: (2004-09-01)

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
por: Barber, T, et al.
Publicado: (2011)

Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.
por: Karavitaki, N, et al.
Publicado: (2010)

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature
por: Eng-Loon Tng, et al.
Publicado: (2023-03-01)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
por: Karavitaki, N, et al.
Publicado: (2013)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
por: Karavitaki, N, et al.
Publicado: (2013)

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
por: Grossman, A, et al.
Publicado: (1987)

Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
por: Lambert, K, et al.
Publicado: (2017)

Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes
por: Lambert, K, et al.
Publicado: (2017)

The modern management of macroprolactinomas.
por: Grossman, A
Publicado: (1991)

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.
por: Suliman, S, et al.
Publicado: (2007)

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
por: Soni, A, et al.
Publicado: (2008)

Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
por: Turner, H, et al.
Publicado: (1999)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
por: Grossman, A, et al.
Publicado: (1985)

Macroprolactinoma in an adolescent female with primary amenorrhoea
por: Ning Zhang, et al.
Publicado: (2024-12-01)

Rathke's cleft cysts.
por: Trifanescu, R, et al.
Publicado: (2012)

Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed.
por: Trifanescu, R, et al.
Publicado: (2011)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Elle Vermeulen, et al.
Publicado: (2020-05-01)

Clinical Characteristics of Macroprolactinomas and Response to Medical Therapy
por: Pooja Tiwari, et al.
Publicado: (2024-06-01)

Impulse control disorders and dopamine agonists
por: D. Martins, et al.
Publicado: (2021-04-01)

Cluster Headache Secondary to Macroprolactinoma with Ipsilateral Cavernous Sinus Invasion
por: M. J. Levy, et al.
Publicado: (2012-01-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Xiaoshuang Liu, et al.
Publicado: (2019-01-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Claudia Pivonello, et al.
Publicado: (2022-01-01)

Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment
por: Anne de Bray, et al.
Publicado: (2018-07-01)

Recurrent Macroprolactinoma with Malignant Conversion to Carcinoma with Spinal Metastasis
por: Madeline Mori, et al.
Publicado: (2021-01-01)

Meningitis and CSF Rhinorrhea as Initial Presentations of Untreated Macroprolactinoma
por: Li Yunkai Andrew, et al.
Publicado: (2014-05-01)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
por: Karavitaki, N, et al.
Publicado: (2005)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
por: Karavitaki, N, et al.
Publicado: (2005)

Dopamine Agonists and Pathologic Behaviors
por: Brendan J. Kelley, et al.
Publicado: (2012-01-01)

Myxedema Coma Associated with Macroprolactinoma: Case Report and Review of the Literature
por: Elizabeth Jasola Omoniyi, et al.
Publicado: (2022-01-01)

Suppurative meningitis: A life-threatening complication in male macroprolactinomas
por: Farida Chentli, et al.
Publicado: (2013-01-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
por: Irena A. Ilovayskaya, et al.
Publicado: (2023-12-01)

Dopamine agonists for restless legs syndrome
por: Pran Phakdeekitcharoen, et al.
Publicado: (2025-02-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Nadiya Barabash, et al.
Publicado: (2022-11-01)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.
por: Gorgoraptis, N, et al.
Publicado: (2012)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, N, et al.
Publicado: (2012)

Macroprolactinemia in a Patient with Invasive Macroprolactinoma: A Case Report and Minireview
por: Atanaska Elenkova, et al.
Publicado: (2013-01-01)

Untreated Giant Macroprolactinoma with Chronic Cerebrospinal Fluid Leakage: An Unusual Complication
por: Mohamad Nazrulhisham Mad Naser, et al.
Publicado: (2019-01-01)

Pituitary apoplexy in an adolescent male with macroprolactinoma presenting as middle cerebral artery territory infarction
por: Pankaj Agrawal, et al.
Publicado: (2022-12-01)

Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
por: Karavitaki, N, et al.
Publicado: (2006)